Bronchodilators Market Size, Share & Trends Analysis Report By Disease (Asthma, COPD), By Route Of Administration (Inhalable, Oral), By Drug Class (Beta-Adrenergic, Anticholinergics), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global bronchodilators market size was estimated at USD 22.19 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 3.29% by 2030. The bronchodilators market is witnessing growth due to factors such as the growing geriatric population, increasing prevalence of lung diseases, and rising awareness about lung disease treatment aided by escalating R&D efforts by key players operating in the market.

The U.S. market is expected to expand at a compound annual growth rate (CAGR) of 2.91% from 2022 to 2030. The COVID-19 outbreak had a positive impact on the market which can be attributed to the off-label use of bronchodilators for inpatient treatment. Moreover, SARS-CoV-2 weakened the lungs & immunity in patients making them susceptible to lung diseases and viral infections. For instance, as per NCBI in 2020, rhinovirus is the cause of 83% of exacerbations of wheezing in adults which facilitates the demand for nebulizers.

Growing geriatric population globally is expected to act as a key driver for the market as the elderly population has a five times higher mortality rate attributed to asthma and thus requires enhanced support from bronchodilators. Moreover, the number of people aged over 65 is anticipated to triple by 2025 and is projected to aid the bronchodilators market to become profitable.

Furthermore, the development of advanced products is majorly driven by the rising prevalence of respiratory disorders worldwide. Bronchodilators help in relieving the symptoms of respiratory disorders such as asthma and COPD, by opening the airways and counteracting the effects of an attack. This is causing a surge in product approval and launches for treating and managing respiratory disorders which is estimated to supplement the segment growth.

However, the market is significantly hampered owing to the regulatory framework related to bronchodilators. The regulatory approval procedure is frequently critiqued for being excessively slow or lenient when safety issues arise. The regulatory atmosphere is already complex, and the FDA is becoming ever more careful as dependency on bronchodilators is growing. Hence, the stringency of regulations associated with the approval process for bronchodilators is limiting the market growth. Moreover, in December 2022, the U.S. faced a shortage of albuterol inhalers demonstrating an unmet need that can be fulfilled by new generic companies.

Drug Class Insights

The beta-adrenergic bronchodilators segment dominated the market in 2022 with the largest revenue share of more than 40.0% and is expected to expand at the fastest CAGR of 3.33% during the forecast period. Beta-adrenergic bronchodilators relax the muscles that surround the airways for dilating bronchial airways. This class of medications are beta-2 agonists and target smooth muscle cell receptors for the dilation of airways. Major products in the short-acting category include levalbuterol (Xopenex HFA), albuterol (Proair HFA, Proventil HFA, AccuNeb, Ventolin HFA), and epinephrine injection. Albuterol is the major revenue-generating molecule in this category and an increasing number of generic approvals and new launches are being observed for this molecule by FDA to meet the rising demands. For instance, in May 2022, Teva Pharmaceutical Industries Ltd. represented the potential of ProAir Digihaler (albuterol sulfate) inhalation powder that can be used for the treatment of patients with Asthma.

Anticholinergic bronchodilators segment is expected to show a lucrative growth rate during the forecast period. The growth of the segment is attributed to the availability of anticholinergics in both long and short-acting formulations. Furthermore, anticholinergic bronchodilators prevent the parasympathetic nerve reflexes from constricting the airways, allowing the airways to remain open. Chronic obstructive pulmonary disease (COPD) is commonly treated with anticholinergic bronchodilators which are considered as the first line of therapy for the treatment of COPD. However, the growth of the segment is hampered is linked to reduced health outcomes, especially in the elderly, with a 60% increase in fall-related hospitalizations, a 50% rise in dementia risk, and a 30% increase in mortality associated with anticholinergics.

Route of Administration Insights

The nasal (Inhalable) segment held the largest market share of 51.8% in 2022 and is further expected to expand at the fastest CAGR of 3.28% over the forecast period. Nasal or inhalable route is the most widely used route of administration for bronchodilators. This route of administration is widely used as metered-dose inhaler (MDI), nebulizer, dry powder inhaler, and soft mist inhaler. As per a study by the International Journal of Chronic Obstructive Pulmonary Disease, the use of soft mist inhaler aerosol provides a longer-lasting and slower-moving dose when compared to MDI. Moreover, the launch of a generic version of nasal formulations is further propelling the growth of the market. For instance, in March 2022, Mylan’s first generic of Symbicort, an inhalation aerosol received FDA approval for the treatment of asthma and COPD.

Oral segment is expected to show lucrative growth over the forecast period. The growth of the segment is attributable to it being the second most preferred mode of administration amongst clinicians and patients as they avoid the adverse effects of injectable administration, thereby driving the segment's market share. In addition, they are usually less expensive with a lot of generic substitutes available in the market, and are considered second most preferred mode of administration amongst clinicians and patients as they avoid the adverse effects of injectable administration.

Disease Insights

The asthma segment accounted for the largest revenue share of 41.9% in the market in 2022 and expanded at the fastest CAGR of 3.31% over the forecast period. The dominance of the segment is attributed to the increasing prevalence of asthma among the population. According to WHO estimates asthma affected 262 million patients globally with inflammation and narrowing of the lungs being common. The segment has a strong research pipeline, with many candidates in late-stage or mid-stage development. Several double and triple combination inhalers for asthma are also in the last stages of development, with the objective of increasing medication adherence. For instance, in May 2022, PT027 (Albuterol/Budesonide Fixed-Dose Combo), developed through AstraZeneca and Avillion collaboration, displayed promising results in Phase III clinical trials and is accepted by FDA as new drug application filed by both companies.

The Chronic obstructive pulmonary disease (COPD) segment is expected to show lucrative growth during the forecast period. The growth of the segment is associated with the rising geriatric population as a result of which the demand for COPD drugs is also expected to surge. Individuals aged over 65 years are at higher risk of developing COPD. The prevalence of COPD is lower than asthma, however, leads to 5% of deaths globally. Overdiagnosis is also a factor associated with a high prevalence of COPD. The condition is more prevalent in low- and middle-income countries and has a high rate of mortality

Regional Insights

North America dominated the bronchodilators market in 2022, which is attributed to the increasing prevalence of COPD and asthma, a rising geriatric population, and increasing demand for high-efficacy and fast-acting drugs in the region. The rising COPD cases in the region is attributed to air pollution, working with chemicals, dust and fumes, secondhand smoke, and a history of childhood lung infection. According to the American Lung Association, cigarette smoking is responsible for 85 to 90% of all COPD cases. The region has a high number of smokers which is estimated to be 30.8 million adults in the U.S. and more than 16 million people living in the region are suffering from smoking-related diseases.

Asia Pacific is expected to be the fastest-growing region over the forecast period. The region shows a high prevalence of asthma. It is reported that asthma is one of the leading causes of death and is a major non-communicable disease in the region. Moreover, the region shows the presence of key players such as Glenmark Pharmaceuticals Limited and Cipla Inc. which gives a competitive edge to the region as these companies specialize in low-cost generic bronchodilators. Moreover, the launch of advanced inhaler bronchodilators is further propelling the growth of the market. For instance, in October 2020, Zydus Cadila launched its pressurized metered-dose inhaler, Forglyn pMDI, priced at Rs 495 per pack for patients suffering from COPD in India.

Key Companies & Market Share Insights

The key players operating in the bronchodilators market are focusing on partnerships, geographical expansion, and strategic collaborations in emerging and economically favorable regions. For Instance, in October 2022, AeroRx Therapeutics collaborated with HCmed Innovations for the development of novel therapeutics combination of bronchodilators for the treatment of people with COPD. Some of the prominent players in the global bronchodilators market include:

• GSK plc.

• AstraZeneca

• Teva Pharmaceutical Industries Ltd.

• Cipla Inc.

• Mylan N.V.

• Merck & Co., Inc.

• Novartis AG

• Boehringer Ingelheim International GmbH.

• Sun Pharmaceutical Industries Ltd.

• Glenmark Pharmaceuticals Limited

Bronchodilators Market Report Scope

Global Bronchodilators Market Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the bronchodilators market on the drug class, route of administration, disease, and region

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Beta-Adrenergic Bronchodilators

  • Xanthine Derivatives

  • Anticholinergic Bronchodilators

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral

  • Nasal (Inhalable)

  • Injectable

• Disease Outlook (Revenue, USD Million, 2018 - 2030)

  • Asthma

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait